If one only looks at the capital market's price charts, Mindray Medical International Ltd appears to be caught in a prolonged ebb tide.

Its market capitalization has shrunk, falling back to levels seen before 2020. The path to a Hong Kong listing has been fraught with twists and turns and remains unrealized. Coupled with a volatile earnings growth trajectory, these three dark clouds have cast a shadow, plunging market sentiment into unprecedented gloom. Across major investment forums, narratives about this medical device leader reaching its "growth peak" or its "moat collapsing" have consequently gained significant traction.

However, looking beyond this noise, two questions deserve serious consideration: Has Mindray Medical, which firmly holds the top spot in China's medical device sector, truly "lost its way"?

A deeper inquiry is: In the global marathon of the medical industry, is it possible for Chinese medical device companies to transcend cycles and become truly global giants?



Mispriced Market Cap and Past Cycles

The broader market narrative dictates the fate of individual stocks. To understand Mindray's falling market value, one must first step back and observe the macro environment.

Over the past few years, global capital markets have undergone a dramatic shift in thematic focus. The medical device sector, once fervently pursued by capital, is now facing overall pressure.

The reason lies in this thematic switch—the AI industry has become the new narrative for capital markets, while medical devices are seen as the "old economy" lacking imagination. Capital chases hotspots, pursues new themes, and seeks excess returns, leading to a revaluation across sectors.

This is not a predicament unique to Mindray but a microcosm of the entire healthcare sector experiencing the growing pains of "de-bubbling" during a thematic transition.

During this process, the pains of domestic medical compliance rectification, geopolitical frictions, and the sentiment shock from centralized procurement policies... various short-term negative factors have been amplified by the market.

This has led to a capital drain effect. For instance, in Q1 2026, the Social Security Fund 113 Portfolio reduced its allocation to Mindray by 18.06%, and the E Fund ChiNext ETF slashed its holdings by 48.97%.

When profit-chasing and fear jointly dominate trading, a company's stock performance can easily become severely detached from its actual operational foundation.

Under these circumstances, a most easily overlooked truth is that the capital market's neglect reflects the cycle of market funds, not the end of a company's lifecycle. A depressed stock price represents the collapse of past valuation biases, not the collapse of the company's fundamental business.

Therefore, equating a market cap retracement with corporate decline is the height of lazy investment thinking. Within the market value Mindray has lost lies capital's repayment for the excesses of a past狂热 cycle, not a final verdict on the future of a leading company.



The Road Ahead and the Path Behind

If market capitalization is a rearview mirror distorted by sentiment and cycles, then what should we use to measure a company's future?

The answer lies in the difference between two sets of indicators: lagging indicators and forward-looking indicators.

Financial data is a typical lagging indicator. It can only show how much money Mindray earned last year, how stable its market share was, and how generous its dividends were.

Using yesterday's financial report to judge tomorrow's Mindray inevitably leads to pessimism—the slowdown in revenue and profit growth is an undeniable fact. However, what truly determines a company's market position several years from now are forward-looking competitive metrics.

These metrics are quietly developing within Mindray's current business framework.

The first metric is Mindray's internationalization.

In 2025, Mindray's international business revenue reached 17.65 billion yuan, historically exceeding 53% of total revenue. Overseas markets surpassed domestic ones for the first time, becoming the largest "ballast." In Q1 2026, the European market share increased by another 25%, and developing markets grew by 15%.

Mindray's lead in international business revenue over its peers is not just about scale but a qualitative leap.

True internationalization is not merely about exporting products but achieving global symbiosis in R&D, compliance, and clinical insight. In 2025, revenue from international high-end strategic clients contributed to 15% of total international revenue.

In the United States, Mindray covers approximately 80% of large hospital networks (IDNs), with nearly 35% of these hospitals using two or more of its product combinations, indicating deepening customer loyalty. Growth in the European market is even more impressive, achieving 17% year-on-year growth in 2025 on a high base from 2024, covering over 660 teaching hospitals.

From simply "exporting" equipment to establishing localized teams and cultivating high-end client groups in a "globalization" strategy, Mindray's footprint in Europe, Latin America, Asia-Pacific, and other regions has taken root, beginning to compete with international giants for core client groups. This depth of internationalization is a moat difficult for domestic peers to replicate in the short term.

The second metric is the major turnaround domestically.

In China, after experiencing the pains of centralized procurement and industry compliance rectification, Mindray has signaled in investor communications that domestic business growth is expected to turn positive within the current year. The growth rate of its net inventory balance has sharply narrowed from 19.57% in 2024 to 5.18% in 2025.

This indicates that the most difficult period of destocking and policy adaptation is over. Furthermore, healthcare system construction remains a core part of the national "15th Five-Year Plan" and "Healthy China 2030," ensuring a solid foundation of刚性需求. Under the direction of "quality competition" within the entire medical system, the hierarchical positioning is clearer: tertiary hospitals tackle complex and critical illnesses, secondary hospitals serve as intermediaries, and primary care institutions handle common ailments. This trend provides amplified space for domestic medical device substitution to extend into the high ground of top-tier (Grade 3A) hospitals.

The third metric is digitalization and intelligence.

This is Mindray's most ambitious forward-looking布局. If high-quality products are the "knock on the door" to international markets, then future-oriented digital-intelligent solutions are the key to solving global healthcare systems' challenges of "reducing costs and increasing efficiency" and "doctor and nurse shortages."

Within the ecosystem of digital-intelligent solutions, Mindray sells not isolated devices but hospital-wide solutions that address departmental pain points and integrate data across campuses. This not only increases per-customer value but also upgrades the customer relationship from a "transactional" to a "symbiotic" one.

As of Q1 2026, Mindray's RuiZhi ecosystem solutions have been installed in over 1,300 hospitals, with tertiary hospitals accounting for more than 80%. In international markets, the RuiZhiLian M-Connect platform has secured over 900 projects cumulatively, with 50 new projects signed in Q1. The RuiYing ecosystem has covered all 31 provinces, municipalities, and autonomous regions in China, as well as regions like the Middle East, Africa, Latin America, and Southeast Asia internationally, achieving over 27,500 cumulative global installations. In Q1 2026, over 1,500 new units were installed globally.

In the in-vitro diagnostics field, Mindray Medical is accelerating the clinical deployment of the RuiJian ecosystem and the Qiyuan Inspection large model. This model has already been piloted at Shenzhen Hospital of Southern Medical University and the Affiliated Cancer Hospital of Guangzhou Medical University, with the number of installation hospitals expected to continue increasing in 2026.

The significance of these three metrics is not as immediately visible as surging revenue or profit, nor as trendy as hot concepts. However, these metrics determine Mindray's positioning in the future market, its next growth drivers, and its differentiation from peers.



Not Stagnation, But Deep Cultivation

Compared to the former "Double Twenty" era (both revenue and net profit growth exceeding 20%), the current Mindray indeed appears slower. However, today's slowness does not signify tomorrow's halt.

Mindray's slowness is dictated by industry规律. The essence of medical devices is high-end manufacturing. It differs from internet commerce, which can rush in based on the lowest common denominator, and from the AI industry, which can create disruptive effects through technological revolutions.

Mindray's slowness is also a function of its earnings base. When a manufacturing company's revenue reaches tens of billions, each percentage point of growth represents fluctuations of hundreds of millions. Replicating high double-digit growth requires exponentially greater effort.

Most importantly, Mindray's slowness is actually a necessary path for Chinese medical device companies to build profound strength for a major leap. On this path, Mindray's three areas of "slow progress" may serve as reliable guides for investing in this company.

The first area of slow progress is in R&D, representing a攻坚期 to reach a leading position.

In the past, Mindray rapidly captured significant market share through a "me-too, me-better" strategy, giving it the appearance of fast, light-footed progress. But now, as Mindray steps to the edge of "industrial no-man's land" in超高端 ultrasound, core raw materials for IVD, and外科微创, it faces the need for a重新理解 of underlying technologies. Even acquiring existing technology through M&A requires a process from integration to synergy—this is not a mathematical problem but a chemical one.

The second area of slow progress is in the market, representing a沉淀期 from product export to localized深耕.

Through sales efforts, equipment can be sold worldwide quickly. But delivering成套解决方案 into top medical centers in Europe and America and establishing localized pre- and post-sales teams is an extremely lengthy process.

What Mindray is doing is breaking the stereotype that "Made in China equals low price and低端," building global high-end客户 trust in Chinese medical devices. This shift from a trade model to a跨国运营 model同样 requires time to沉淀.

The third area of slow progress is strategic, representing an演进期 for the digital-intelligent ecosystem.

Digitalization and intelligence is not a process that can be completed by unilateral push, nor is it simply installing software into hardware and connecting it to a network. It is a process that requires users and developers to deeply understand and mutually nurture each other. Clinical needs in hospitals vary widely; large model training requires feeding on massive amounts of real data; algorithms need continuous iteration...

Therefore, what Mindray is doing is陪跑 medical scenarios and growing together with clinical experts. Precisely this meticulous, slow work will ultimately build an生态壁垒 that is difficult to migrate.

Compared to industries that skyrocket overnight, medical devices have never been a sector for making quick money. Looking at the development histories of century-old giants like Medtronic and Siemens Healthineers, they have all without exception experienced the pains of shifting growth gears, undergone business拆分重组, and weathered waves of technological迭代, M&A integration, and cyclical起伏 before finally settling into their positions.

Therefore, Mindray's future does not depend on the gain or loss of a single city or池, nor on the strength or weakness of a quarterly or annual financial report. It depends on whether the company is on the right path and has the unwavering focus to follow that path to the end.

This is a classic case of "slow is fast," and this is the real Mindray Medical.